Completed
PHASE1
INTERVENTIONAL
NCT06313528
A Study to Measure Calorie Consumption and Usage in Participants With Obesity Using LY3437943
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
The main purpose of the study is to look at the effect of the study drug compared to placebo on calorie intake, energy metabolism, and appetite. The study will last up to 6 months and may include up to 20 visits.
Interventions
Name:
LY3437943
Type:
DRUG
Description:
Administered SC
Name:
Placebo
Type:
OTHER
Description:
Administered SC
Primary Outcomes
Measure:
Change from Baseline in Total Calorie Intake at Lunch and Dinner (Combined)
TimeFrame:
Baseline up to Week 17 (inclusive)
Description:
Trial Information
NCT ID
NCT06313528
Status
Completed
Study Type
INTERVENTIONAL
Phases
PHASE1
Sponsor
Eli Lilly and Company
Last Updated
December 15, 2025